Secondary Logo

Journal Logo

Most Popular Articles

Rapid BRAF mutation tests in patients with advanced melanoma: comparison of immunohistochemistry, Droplet Digital PCR, and the Idylla Mutation Platform

Bisschop, Cornelis; ter Elst, Arja; Bosman, Lisette J.; More

Melanoma Research. 28(2):96-104, April 2018.

Results from phase II trial of HSP90 inhibitor, STA-9090 (ganetespib), in metastatic uveal melanoma

Shah, Shalin; Luke, Jason J.; Jacene, Heather A.; More

Melanoma Research. 28(6):605-610, December 2018.

Evidence and interdisciplinary consensus-based German guidelines: surgical treatment and radiotherapy of melanoma

Garbe, Claus; Hauschild, Axel; Volkenandt, Matthias; More

Melanoma Research. 18(1):61-67, February 2008.

Whole-exome sequencing identifies recurrent SF3B1 R625 mutation and comutation of NF1 and KIT in mucosal melanoma

Hintzsche, Jennifer D.; Gorden, Nicholas T.; Amato, Carol M.; More

Melanoma Research. 27(3):189-199, June 2017.

Postsurgical treatment landscape and economic burden of locoregional and distant recurrence in patients with operable nonmetastatic melanoma

Tarhini, Ahmad; Ghate, Sameer R.; Ionescu-Ittu, Raluca; More

Melanoma Research. 28(6):618-628, December 2018.

Prognostic significance of distant metastasis-free interval in patients with relapsed melanoma treated with BRAF with or without MEK inhibitors

Bafaloukos, Dimitrios; Papaxoinis, George; Linardou, Helena; More

Melanoma Research. 29(4):428-434, August 2019.

Clinical experience with combination BRAF/MEK inhibitors for melanoma with brain metastases: a real-life multicenter study

Drago, Joshua Z.; Lawrence, Donald; Livingstone, Elisabeth; More

Melanoma Research. 29(1):65-69, February 2019.

Evidence-based and interdisciplinary consensus-based German guidelines: systemic medical treatment of melanoma in the adjuvant and palliative setting

Garbe, Claus; Hauschild, Axel; Volkenandt, Matthias; More

Melanoma Research. 18(2):152-160, April 2008.

Treatment patterns of adjuvant interferon-α2b for high-risk melanoma: a retrospective study of the Grupo Español Multidisciplinar de Melanoma – Prima study

Espinosa, Enrique; Soriano, Virtudes; Malvehy, Josep; More

Melanoma Research. 26(3):278-283, June 2016.

The impact of patient characteristics and disease-specific factors on first-line treatment decisions for BRAF-mutated melanoma: results from a European expert panel study

Ascierto, Paolo A.; Bastholt, Lars; Ferrucci, Pier F.; More

Melanoma Research. 28(4):333-340, August 2018.

Sarcoid-like reactions in patients receiving modern melanoma treatment

Dimitriou, Florentia; Frauchiger, Anna L.; Urosevic-Maiwald, Mirjana; More

Melanoma Research. 28(3):230-236, June 2018.

Multicenter, real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in Switzerland

Mangana, Joanna; Cheng, Phil F.; Kaufmann, Corina; More

Melanoma Research. 27(4):358-368, August 2017.

Nivolumab monotherapy or in combination with ipilimumab for metastatic melanoma: systematic review and meta-analysis of randomized-controlled trials

Menshawy, Amr; Eltonob, Abdelrahman A.; Barkat, Sarah A.; More

Melanoma Research. 28(5):371-379, October 2018.

A multireferral centre retrospective cohort analysis on the experience in treatment of metastatic uveal melanoma and utilization of sequential liver-directed treatment and immunotherapy

Itchins, Malinda; Ascierto, Paolo A.; Menzies, Alexander M.; More

Melanoma Research. 27(3):243-250, June 2017.

In vitro and in vivo antimelanoma effect of ethyl ester cyclohexyl analog of ethylenediamine dipropanoic acid

Isakovic, Andjelka M.; Petricevic, Sasa M.; Ristic, Slavica M.; More

Melanoma Research. 28(1):8-20, February 2018.

MGMT methylation correlates with melphalan pelvic perfusion survival in stage III melanoma patients: a pilot study

Guadagni, Stefano; Fiorentini, Giammaria; Clementi, Marco; More

Melanoma Research. 27(5):439-447, October 2017.

Show: